Table 5.

Hazard ratio (95% confidence interval) per standard deviation of log‐transformed biomarker for primary outcome between heart failure with preserved ejection fraction patients without vs. with diabetes, adjusted for age, sex, and randomization stratum

Biomarker	Non‐DM n = 132 (27 events)	DM n = 116 (47 events)	Interaction P a
eGFR (mL/min/1.73 m2)	1.21 (0.71, 2.04)	0.56 (0.41, 0.78)	0.042
UPCR (mg/mmol)	0.85 (0.45, 1.63)	1.13 (0.87, 1.48)	0.40
Urinary protein level (mg/dL)	1.47 (0.90, 2.40)	1.27 (0.95, 1.70)	0.60
hs‐CRP (mg/L)	1.27 (0.89, 1.83)	1.29 (0.96, 1.73)	0.87
Uric acid (mg/dL)	1.09 (0.72, 1.63)	1.65 (1.18, 2.29)	0.18
NT‐proBNP (pg/mL)	1.59 (1.04, 2.45)	1.31 (0.97, 1.76)	0.66
hs‐TnT (ng/mL)	2.05 (1.53, 2.76)	1.80 (1.31, 2.47)	0.86
sST2 (ng/mL)	1.48 (0.98, 2.24)	1.62 (1.20, 2.18)	0.64
Aldosterone (ng/L)	1.32 (0.92, 1.88)	1.17 (0.91, 1.50)	0.82
PICP (ng/mL)	0.90 (0.58, 1.42)	0.95 (0.69, 1.30)	0.82
CITP (ng/mL)	0.59 (0.37, 0.92)	0.69 (0.46, 1.03)	0.70
PIIINP (ng/mL)	1.20 (0.80, 1.81)	2.42 (1.62, 3.61)	0.019
MMP‐2 (ng/mL)	1.08 (0.72, 1.62)	0.98 (0.72, 1.33)	0.98
MMP‐9 (ng/mL)	0.81 (0.57, 1.15)	1.00 (0.73, 1.37)	0.47
TIMP‐1 (ng/mL)	1.31 (0.89, 1.93)	1.09 (0.81, 1.48)	0.36
Gal‐3 (ng/mL)	1.15 (0.74, 1.81)	2.12 (1.44, 3.13)	0.034

CITP, collagen type I; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Gal‐3, galectin‐3; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐TnT, high‐sensitivity troponin T; MMP‐2, matrix metalloproteinase 2; MMP‐9, matrix metalloproteinase 9; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PICP, pro‐collagen type I carboxy‐terminal peptide; PIIINP, pro‐collagen type III amino‐terminal peptide; sST2, soluble ST2; TIMP‐1, tissue inhibitor of metalloproteinase 1; UPCR, urinary protein to creatinine ratio.

^aInteraction between biomarker and DM status, adjusted for biomarker–treatment interaction.